Trial Profile

Prospective Observational Study on Predictors of Early On-treatment Response and Sustained Virological Response in a Cohort of Treatment naive HCV-infected Patients Treated With Pegylated Interferons.

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 17 Oct 2016

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Peginterferon alfa-2a (Primary) ; Peginterferon alfa-2b (Primary) ; Ribavirin
Indications Hepatitis C
Focus Therapeutic Use
Acronyms PROPHESYS 3
Sponsors Roche

01 Sep 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
30 Nov 2011 Planned end date changed from 1 Feb 2011 to 1 Dec 2011 as reported by ClinicalTrials.gov.
30 Nov 2011 Actual patients number (1613) added as reported by ClinicalTrials.gov.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com